• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Aptar Pharma banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Tonix gets US patent for the use of intranasal potentiated oxytocin for the treatment of migraine

According to Tonix Pharmaceuticals, the United States Patent and Trademark Office has issued the company US Patent 11,389,473,"Magnesium-Containing Oxytocin Formulations and Methods of Use," which includes claims related to the use of such formulations for the treatment of pain such as migraine headache. The anticipated expiration date for the patent is January 7, … [Read more...] about Tonix gets US patent for the use of intranasal potentiated oxytocin for the treatment of migraine

Atossa to refocus development of AT-H201 on the treatment of radiation-induced lung injury

Atossa Therapeutics said that it has completed the first three parts of a Phase 1/2a trial, which was announced in July 2021, but it will skip the remaining part. Part D had been expected to enroll hospitalized COVID-19 patients; however, the company said that it will instead shift development of the inhaled heparin / n-acetylcysteine therapy to the treatment of … [Read more...] about Atossa to refocus development of AT-H201 on the treatment of radiation-induced lung injury

ARS to merge with Silverback to support development and commercialization of Neffy epinephrine nasal spray

ARS Pharmaceuticals plans to merge with Silverback Therapeutics, the companies said, with the combined company focused on approval and launch of ARS's Neffy (ARS-1) epinephrine nasal spray for the treatment of allergic reactions. Shareholders of Silverback, whose pipeline consists of a therapy for the treatment of chronic hepatitis B in early development, will own a … [Read more...] about ARS to merge with Silverback to support development and commercialization of Neffy epinephrine nasal spray

SoftOx gets funding from European Defense Fund to develop inhalation solution as a military countermeasure

SoftOx Solutions has announced that the European Defense Fund has awarded a 3-year grant of approximately NOK 97 million (~€9.6 million) to the company's subsidiary SoftOx Defense Solutions (SDS) for development of an inhalation solution as a part of a project developing countermeasures against harm from chemical, biologic, radioactive, and nuclear (CBRN) substances. … [Read more...] about SoftOx gets funding from European Defense Fund to develop inhalation solution as a military countermeasure

PTAB rules in Liquidia’s favor, finds another Tyvaso patent’s claims are not patentable

According to Liquidia, the US Patent Trial and Appeal Board (PTAB) has found that none of the claims included in US Patent No. 10,716,793, covering Tyvaso inhaled treprostinil, are valid. The company said that the PTAB ruling would have to be upheld on appeal before it can affect a court ruling holding up final approval of Liquidia's NDA for … [Read more...] about PTAB rules in Liquidia’s favor, finds another Tyvaso patent’s claims are not patentable

Recipharm to develop two inhalation formulations for Transpire Bio

Florida-based startup Transpire Bio announced that it has signed an agreement with Recipharm for development of two inhaled candidates, TRB-1 and TRB-2, for the treatment of asthma and COPD. The company says that the two generic MDIs are "intended for advanced markets." Transpire CEO Xian-Ming Zeng said, "Our mission is to improve access to important, life-saving … [Read more...] about Recipharm to develop two inhalation formulations for Transpire Bio

VisionHealth says Boehringer Ingelheim to cooperate on distribution of the Kata inhaler training app in Germany

German digital health company VisionHealth has announced that it will "cooperate on distribution of inhalation platform Kata" with Boehringer Ingelheim in Germany. The Kata app uses artificial intelligence and augmented reality technology in conjunction with the patient's smartphone camera to provide interactive inhaler use coaching. The company says that the app can … [Read more...] about VisionHealth says Boehringer Ingelheim to cooperate on distribution of the Kata inhaler training app in Germany

TFF Pharmaceuticals expands with new R&D facility

TFF Pharmaceuticals announced that it has leased a new 3,500+ square foot R&D facility in Austin, Texas, USA, that will house additional lab space, as well as equipment for the production of preclinical supplies, significantly expanding the company's capabilities. TFF also said that it will continue its relationship with the University of Texas at Austin, where … [Read more...] about TFF Pharmaceuticals expands with new R&D facility

Theravance, Innoviva selling Trelegy Ellipta royalty interests to Royalty Pharma

According to Theravance Biopharma, the company is selling its stake in Theravance Respiratory Company (TRC), which received royalties from sales of GSK's Trelegy Ellipta fluticasone furoate / umeclidinium / vilanterol DPI. The deal with Royalty Pharma is worth up to $1.5 billion, including $1.1 billion up front, the company said. Theravance Biopharma owns 85% of TRC; … [Read more...] about Theravance, Innoviva selling Trelegy Ellipta royalty interests to Royalty Pharma

NurExone partners with Polyrizon for development of intranasal therapy for spinal cord injuries

Israeli startup NurExone Biologic has announced that it will pay Israeli nasal delivery specialist Polyrizon a total of up to $3,350,000 for development of an intranasal formulation of NurExone's ExoTherapy, exosomes loaded with modified siRNA sequences for the treatment of traumatic spinal cord injuries. The formulation will be based on Polyrizon's Trap and Target … [Read more...] about NurExone partners with Polyrizon for development of intranasal therapy for spinal cord injuries

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Intertek banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews